Supply chain resilience for biopharma and advanced therapies

Build supply chain resilience into bioprocessing

From process development to clinical and commercial biomanufacturing, strengthen supply chains for cell and gene therapies, biologics, and beyond.

Supply resilience from sourcing to delivery

Successful biomanufacturing depends on validated products and processes, yet more than 75% of biopharma leaders surveyed in 2025 anticipate major changes to sourcing strategies in the coming years.

To absorb the supply shock waves before they reach you, we've built supply chains that hold steady through changing conditions.

Our supply resilience is bolstered by:

35 manufacturing sites across the globe
Systematic dual sourcing of critical raw materials
Strategic reserves for key products

How we protect your supply

Business continuity management

All bioprocess manufacturing sites are ISO 22301 certified, with site-level contingency plans and crosssite manufacturing transfer protocols to respond to disruptions.

Proactive risk management

We assess risk across 15 000 parts and 1200 suppliers, identifying vulnerabilities before they affect your orders.

Transparent communication

You receive proactive change control notifications across your product portfolio, so you can plan ahead rather than react to surprises.

Supply resilience in practice

From how supply is built to how we work with you day to day, learn about our strategic approach to supporting your operations.

Infrastructure and sourcing

Transparent communication You receive proactive change control notifications across your product portfolio, so you can plan ahead rather than react to surprises. Manufacturing depends on consistency. We design our supply network to reduce dependency, absorb disruption, and maintain continuity. Supply snapshot

Key elements:

Global, multi-site manufacturing to reduce reliance on any one location and support continuity across regions
In-region-for-region supply models to help reduce exposure to global disruption and logistics risk
Strategic reserves for critical products, stored in separate locations
Dual sourcing of key raw materials to reduce single-point-of-failure risk
Defined lifecycle and discontinuation policies to give you advance visibility and time to plan validated alternatives

Supply snapshot

An overview of how and where we invest in a reliable and continuous supply chain

15 000+

parts monitored across the supply chain

1200+

suppliers assessed for risk

$1.6B

committed to capacity expansions between 2019 and 2028

Explore supply chain resilience in detail

When we prioritize protecting your supply, you can stay focused on delivering the next breakthrough, molecule, or clinical milestone.

Security of supply for bioprocessing

Global Biopharma Index 2025

Quality and regulatory support

Frequently asked questions about supply chain resilience

What is supply chain resilience in biopharma?

Supply resilience in biopharma refers to the ability of pharmaceutical and biotechnology companies and their suppliers to anticipate, withstand, and recover from disruptions in their supply chains—ensuring uninterrupted production and delivery of critical therapies.

Why is supply resilience critical for biopharma companies?

Supply resilience is essential in biopharma because disruptions can delay lifesaving treatments, impact regulatory compliance, and lead to substantial financial or reputational risks.

What are the biggest supply chain risks in biopharma?

Common risks include raw material shortages, supplier concentration, geopolitical instability, regulatory changes, cold chain failures, and demand volatility—each of which can undermine supply resilience.

What should companies look for in a resilient biopharma supplier?

Companies should look for suppliers with strong quality standards, reliable delivery performance, global capabilities, and a demonstrated commitment to supply continuity.

What role do suppliers play in biopharma supply chain resilience?

Suppliers are a critical part of supply chain resilience, as their ability to maintain consistent quality, availability, and delivery directly impacts the broader biopharma supply chain.

How can suppliers strengthen supply chain resilience in biopharmaceutical manufacturing?

Suppliers can strengthen supply chain resilience by implementing strategies that reduce risk and support continuity, including:

Multi-site and regional manufacturing networks
Dual or multiple sourcing of critical raw materials
Continuous supplier monitoring and risk assessment
Inventory strategies for high-risk materials
Formal business continuity and crisis management systems

Together, these approaches help maintain reliable supply across development, clinical, and commercial stages—even when conditions change.

Learn more about supply resilience

Questions about our security of supply program? Get in touch below.

Shop in your local currency and language